美女免费一级视频在线观看

In April 2023, Oxford PharmaGenesis CEO Chris Winchester spoke excitedly about his company’s burgeoning relationship with Pfizer. This year, he and the company’s other leaders are positively giddy about the evolution of the relationship and the work that has flowed from it.

“This time last year, we weren’t necessarily in the strongest situation with them,” admits COO Richard White. “But we’ve now reached a point where not only have we turned it around, but we’ve also been awarded additional business. So it has shown through in our performance.”

On the back on that Pfizer work — as well as expanded engagements with Takeda, Ipsen, Otsuka, Shionogi and Alnylam Pharmaceuticals — Oxford PharmaGenesis saw revenue rise by 13%, to $40.4 million from $35.9 million the year prior. North American staff size fell from 91 full-timers at the start of 2023 to 74 at the end of the year (global staff size similarly declined, from 450 to 416), but business director, U.S. Jill Wund doesn’t view this as a negative. 

“Initially, we had to focus on the local management team to make sure we had the right players — the right people rowing in the same direction,” she explains. “We took the opportunity to streamline processes and make things more efficient, so that our teams are now better partners to the clients that we’re working with .… The structural efficiency changes really improved our functions.”

Wund, who started at Oxford PharmaGenesis in January 2018 as human resources director, assumed oversight of U.S. health operations in 2023. She replaced Brian Falcone, who left the company after nearly a decade to serve as strategic business unit lead at MedThink SciCom.

Unlike many of its peers in the medcomms space, Oxford PharmaGenesis is very specific in its self-definition. Some time ago, it rebranded itself as a health science communications consultancy, as opposed to a medical communications agency. White says the distinction isn’t merely a matter of semantics. 

“We made a very deliberate choice to choose a new terminology, because the approach we bring, which we call health science, is a truly unique approach. The idea is that it delivers value to all of our clients and stakeholders,” he explains. “For biopharma companies, the challenge is often that they’re siloed themselves. They need to be talking in an aligned way to each of their customers or stakeholders, and we can help them do that.”

Winchester, meanwhile, points to another aspect of Oxford PharmaGenesis that he believes differentiates it from the competition: its independence.

“There are no external investors in the company. We are owned by the people who run the company, so our clients can deal directly with the people who ultimately call the shots,” he explains. “So we can look at each other around the table and say, ‘This seems like a good idea. Shall we have a go at it? Yeah, let’s do it.’ That’s quite refreshing for our clients.” 

. . .

Work we wish we did

The Bridge, an animated video created by Klick Health for Pets Are Wonderful Support (PAWS) NY, which helps New York City residents who are at risk of losing their pets due to physical and financial obstacles. The campaign is centered on the story of an abandoned pet who saves a man from suicide. It makes the case for the importance of humans and pets in each others’ lives. — Winchester

Click to see Oxford PharmaGenesis Agency 100 2023 Profile.

Click here to return to the MM+M Agency 100.